Subscribe To
VYNE / 4 Penny Stocks That Are Trending on Reddit Right Now and Why
VYNE News
By Zacks Investment Research
April 20, 2023
VYNE Gains on Preclinical Data for IPF Candidate
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis. more_horizontal
By Zacks Investment Research
May 12, 2022
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the num more_horizontal
By GlobeNewsWire
May 6, 2022
VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10th
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical compa more_horizontal
By PennyStocks
April 7, 2022
3 Penny Stocks Under $1 That Are on Fire Today
Are these under $1 penny stocks worth buying this month? The post 3 Penny Stocks Under $1 That Are on Fire Today appeared first on Penny Stocks to B more_horizontal
By Benzinga
March 30, 2022
VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis
VYNE Therapeutics Inc (NASDAQ: VYNE) announced positive preclinical data from its VYN201 program in the rheumatoid arthritis (RA) animal model. The more_horizontal
By Benzinga
March 7, 2022
VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor more_horizontal
By Benzinga
March 7, 2022
VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor more_horizontal
By Benzinga
March 7, 2022
VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic autoimmune depigmenting disor more_horizontal